What If I Get Pregnant While on GLP-1 Medication?
Urgent guidance on what to do if you discover you are pregnant while taking semaglutide, tirzepatide, or other GLP-1 medications, including steps to take immediately.
More on What If Questions
Urgent Action Required
If you have just discovered you are pregnant while on a GLP-1 medication: Stop the medication immediately and contact your OB-GYN as soon as possible. Do not take your next scheduled injection. This is not an emergency, but prompt action is important.
What to Do Right Now
Step 1: Stop the Medication
Do not take your next dose. There is no need to "taper off" -- simply stop taking the medication immediately.
Step 2: Contact Your OB-GYN
Call your OB-GYN or midwife within 24-48 hours. Inform them of the specific GLP-1 medication, dose, and dates of recent injections.
Step 3: Notify Your GLP-1 Provider
Let your prescribing provider know about the pregnancy so they can update your medical records and discontinue refills.
Step 4: Start Prenatal Vitamins
Begin taking a prenatal vitamin with folic acid immediately if you are not already taking one.
What We Know About GLP-1 Exposure in Pregnancy
Animal Studies
Animal studies using doses higher than human therapeutic doses showed fetal growth restriction and some developmental effects. However, animal data does not always translate to human outcomes.
Human Data (Limited)
Post-marketing reports and case series of inadvertent first-trimester exposure have not shown a clear pattern of birth defects. Many exposed pregnancies have resulted in healthy babies, though data is still limited.
Timing Matters
Earlier discontinuation reduces exposure risk. Most organ formation occurs between weeks 3-8 of pregnancy. The sooner you stop, the less total fetal exposure.
Moving Forward
While discovering an unplanned pregnancy on GLP-1 medication can be stressful, the available evidence is reassuring that early, inadvertent exposure does not appear to carry high risk. Your OB-GYN will guide monitoring and can address your specific concerns.
Focus on standard prenatal care: proper nutrition (especially important if your appetite was reduced on GLP-1 therapy), prenatal vitamins, regular OB appointments, and recommended screenings.
Frequently Asked Questions
Will GLP-1 medication harm my baby?
Animal studies have shown potential fetal harm at high doses, but human data is limited. Many women have had healthy pregnancies after early GLP-1 exposure. The risk depends on timing and duration of exposure. Discontinue immediately upon discovering pregnancy and consult your OB-GYN.
How quickly does GLP-1 medication leave my system?
Semaglutide has a half-life of about 7 days, taking approximately 5-7 weeks to fully clear. Tirzepatide has a half-life of about 5 days, clearing in approximately 3-5 weeks. This is why the recommended washout before planned conception is 2 months for semaglutide and 1 month for tirzepatide.
Should I be extra worried if I took my injection after conception?
Try not to panic. Many pregnancies progress normally after early GLP-1 exposure. The earlier you stop the medication, the better. Your OB-GYN will likely recommend additional monitoring but in most cases, early inadvertent exposure has not been associated with major issues in human reports.
Will my OB-GYN need to do additional monitoring?
Likely yes. Your OB-GYN may recommend additional ultrasounds and fetal monitoring, especially during the first trimester, to ensure normal development. Be sure to inform your OB-GYN about the specific medication, dosage, and dates of your last injection.
Can I restart GLP-1 medication after giving birth?
GLP-1 medications should not be used while breastfeeding due to insufficient safety data. After you finish breastfeeding (or if not breastfeeding), you can discuss resuming GLP-1 therapy with your provider to address postpartum weight management.
After Your Pregnancy Journey
When you are ready to resume weight management, our team is here to help. Compounded semaglutide from $99/mo, tirzepatide from $125/mo.
Explore Treatment OptionsMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).